Browse TNFSF15

Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 15, secreted form: Secreted.
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.

> Gene Ontology
 
Biological Process GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007250 activation of NF-kappaB-inducing kinase activity
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0032147 activation of protein kinase activity
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0038061 NIK/NF-kappaB signaling
GO:0042107 cytokine metabolic process
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045860 positive regulation of protein kinase activity
GO:0045862 positive regulation of proteolysis
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0071356 cellular response to tumor necrosis factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFSF15 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFSF15 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFSF15 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1250.597
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0080.986
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2230.538
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0010.998
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5140.634
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6540.621
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1860.675
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1650.86
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3830.656
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4580.334
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5260.408
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0570.747
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFSF15 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF15. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF15. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF15.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF15. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFSF15 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFSF15 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFSF15
Nametumor necrosis factor (ligand) superfamily, member 15
Aliases TL1; VEGI; TL1A; VEGI192A; MGC129934; MGC129935; vascular endothelial cell growth inhibitor; TNF superfamily ......
Chromosomal Location9q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFSF15 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.